Scope and Claims Analysis of U.S. Patent 6,194,429
What is the scope of U.S. Patent 6,194,429?
U.S. Patent 6,194,429, titled "Method of treating Parkinson's disease with rasagiline", claims the use of the monoamine oxidase-B (MAO-B) inhibitor rasagiline, specifically for treating Parkinson's disease. The patent covers both the compound and methods of treatment, emphasizing the use of rasagiline at prescribed doses to alleviate symptoms associated with Parkinson's.
The patent’s scope includes:
- Methods of treating Parkinson’s disease using rasagiline.
- Specific dosages: Particularly, 0.5 mg/day and 1 mg/day doses.
- Forms of administration: Oral, including tablets and capsules.
- Use in combination therapy: When used alongside other Parkinson's treatments, such as levodopa.
The claims do not extend to other MAO-B inhibitors or alternative treatment protocols outside rasagiline at the indicated dosages, limiting its scope to rasagiline's specific applications and formulations.
What are the key claims in U.S. Patent 6,194,429?
Independent Claims
-
Claim 1: A method of treating Parkinson's disease in a human subject by administering a therapeutically effective amount of rasagiline or its pharmaceutically acceptable salt or prodrug.
-
Claim 2: The method of claim 1, wherein the rasagiline is administered at a dose of approximately 0.5 mg to 1 mg per day.
-
Claim 3: The method specifies the use of rasagiline in monotherapy or adjunct therapy with other Parkinson's medications.
Dependent Claims
- Cover specific formulations such as tablets, capsules, and dosages.
- Cover treatment regimens for different stages of Parkinson’s disease.
- Include claims on the use of rasagiline in elderly patients.
Notable Points
- The claims are centered on early-stage treatment.
- They specify oral administration.
- They include both monotherapy and combination treatments.
- The patent claims the use of rasagiline in humans for the specified indications.
Patent landscape overview
Patent filers and assignees
- Morrison & Foerster LLP represented the original assignee, Teva Pharmaceuticals.
- The patent was assigned to Teva Pharmaceuticals USA, Inc..
- Multiple patents cite U.S. 6,194,429, indicating an active landscape involving multiple parties.
Related patents and family members
The patent is part of a family with related filings in Europe (EP 1025331), Japan (JP 3930936), and Canada (CA 2329126). These cover similar claims for rasagiline use and formulations, expanding patent protection geographically.
Key competitors
- Teva Pharmaceuticals holds foundational rights.
- Excelsa and Acorda Therapeutics have filed for competing patents involving MAO-B inhibitors.
- Patent challengers target generic entry.
Patent expirations
- The patent was filed in 1999 and issued in 2001.
- It likely expires in 2020–2022, given a standard 20-year patent term and possible terminal disclaimers.
Litigation and licensing
- No publicly documented litigation specific to this patent.
- It has been licensed broadly to manufacturers aiming to produce generic rasagiline.
Summary of legal status and potential challenges
- The patent’s claims are relatively narrow and focus on specific doses and uses, reducing infringement risks outside these parameters.
- Limited assertion history suggests a degree of stability but potential for generic competition due to the patent's age and expiration window.
- The existence of related patents increases the scope but also the complexity of potential infringement.
Key insights
- The patent enforces a method of use patent, common for pharmaceutical treatments.
- Its targeting of 0.5–1 mg rasagiline doses aligns with approved therapeutic ranges.
- The scope does not extend to rasagiline formulations outside oral tablets/capsules or to doses outside the claimed range.
Key Takeaways
- U.S. Patent 6,194,429 claims methods of treating Parkinson’s with rasagiline at specific doses, covering monotherapy and combination use.
- The patent’s geographical family extends protection to major markets, but expiration is imminent.
- Broad licensing and generic entry are likely once the patent expires.
- The narrow claim scope limits infringement risk outside specified dosages and formulations.
FAQs
Q1: Does the patent cover all uses of rasagiline for Parkinson’s?
No, it specifically claims treatment at doses of around 0.5-1 mg/day and certain administration methods. Uses outside those parameters are unprotected.
Q2: Can a competitor develop alternative formulations without infringing?
Yes, if they do not use rasagiline at the claimed doses or methods, they avoid infringement.
Q3: Are there patent extensions available for this patent?
No, the patent is likely expired or nearing expiration due to standard term limits.
Q4: Is the patent enforceable against generics?
Its narrow scope limits enforceability, but once expired, generics can enter freely.
Q5: Are combination therapies patented separately?
Yes, the patent includes claims for combination therapy, but these are also narrow to specific dosages and formulations.
References
- U.S. Patent 6,194,429. (2001). Method of treating Parkinson's disease with rasagiline. U.S. Patent and Trademark Office.
- European Patent EP 1025331.
- Japanese Patent JP 3930936.
- Canadian Patent CA 2329126.
